Bartonella in Liver Transplant Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02595710|
Recruitment Status : Recruiting
First Posted : November 3, 2015
Last Update Posted : February 13, 2018
|Condition or disease||Intervention/treatment|
|Cryptogenic Cirrhosis Cryptogenic Chronic Hepatitis||Other: skin punch biopsy collection Other: Blood collection Other: Urine sample collection|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Undetected Bartonella Spp. Infection Puts Liver Transplant Patients at Great Risk|
|Study Start Date :||December 2013|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2021|
Blood Collection Skin Punch Biopsy Collection Urine Sample Collection
Other: skin punch biopsy collection
Four-mm skin biopsies from non-lesional skin will be acquired from the patients, processed using our published techniques with Bartonella biomarkers, and imaged using confocal microscopy.
Other: Blood collection
Blood will be tested for presence of Bartonella DNA and Bartonella antibodies using the Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid culture, enriched agar plating and molecular techniques.Blood smears will be analyzed for presence of intra-erythrocytic Bartonella spp. by immunostaining.
Other: Urine sample collection
Urine samples will be collected and analyzed for Bartonella spp specific microRNAs.
- Liver transplant subject that show evidence of Bartonella DNA and Bartonella antibodies using the Alpha Proteobacterium Growth Medium (BAPGM) [ Time Frame: 90 weeks ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02595710
|Contact: Marna E Ericson, email@example.com|
|United States, Minnesota|
|University of Minnesota Medical Center||Recruiting|
|Minneapolis, Minnesota, United States, 55455|
|Contact: Marna E Ericson, phd 612-624-2995 firstname.lastname@example.org|
|Principal Investigator:||Marna E Ericson, phd||University of Minnesota - Clinical and Translational Science Institute|